Table 2.
Description of liver dysfunction between non-severe and severe among included studies
| Study, year | Setting | Country | Sample (non-severe/severe) | Age (non-severe/severe) | Chronic liver disease (non-severe/severe) | ALT (non-severe/severe) | AST (non-severe/severe) | TBIL. (non-severe/severe) | Female | NOS | |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Chen guang et al. [17], 2020a |
Isolation ward | China | 10/11 | 52.0(42.8–56.0)/61.0 (56.5–66.0) | NA | 16.0 (13.3–21.8)/42.0 (32.5–50.0) | 24.0(21.5–26.5)/47.0 (28.0–74.5) | 7.8 (6.4–9.5)/8.8 (7.9–10.5) | 1/3 | 7 | |
| Zheng et a. [18], 2020 | Isolation ward | China | 131/30 | 40 (31–51)/57 (46.5–66) | 4/0 | 19.3 (14.6–17.8)/23.9 (17.6–35.3) | 23.4 (19.0–28.8)/31.6 (25.9–49.36) | 10.7 (8.18–15.3)/12.7 (9.2–16.9) | 65/16 | 7 | |
| Wan et al. [11], 2020 | Isolation ward | China | 95/40 | 44(33–49)/56(52–73) | 1/1 | 21.7(14.8–36.9)/26.6(14.5–33.3) | 22.4(16.9–30.5)/33.6(25.7–44.2) | 8.6(5.6–14)/9.8(7.8–15.6) | 43/19 | 8 | |
| Zhang et al. [19], 2020b | Isolation ward | China | 84/31 | 43.96 ± 14.84/64.58 ± 13.26 | 3/2 (Hepatitis B) | 21.22 ± 12.67/37.87 ± 32.17 | 24.39 ± 9.79/38.87 ± 22.55 | 10.27 ± 4.26/14.12 ± 6.37 | 55/11 | 7 | |
| Guan et al. [20], 2020c | Isolation ward | China | 926/173 | 45.0(34.0–57.0)/52.0 (40.0–65.0) | 22/1 (Hepatitis B) | 120/606 vs 38/135 | 112/615 vs 56/142 | 59/594 vs 17/128 | 386/73 | 8 | |
| Ji et al. [21], 2020 | Isolation ward | China | 163/39 |
42.9 (32.6 - 51.8)/55.1 (43.7 -71.8) |
42/34 (NAFLD) 5/2 (HBsAg) |
82/163 vs 19/39 | 24/163 vs 10/39 | 13/163 vs 4/39 | 77/12 | 7 | |
| Cai et al. [8]. 2020d | Isolation ward | China |
233/85 (A) 47/43 (B) |
NA |
78/60 (A) 28/41 (B) |
41 (23–65)/67 (47–100) (A) 84 (42–136)/96 (63–159) (B) |
34(27–45)/58(41–93) (A) 45(29–81)/80(56–145) (B) |
19 (13–26)/22 (18–28) (A) 22 (15–41)/25 (19–32) (B) |
NA | 7 | |
| Li et al. [10], 2020e | Isolation ward | China | 279/269 | 56 (44–66)/65 (54–72) | 2/2 | 61/275 vs 64/266 | 64/275 vs 115/265 | 7/275 vs 17/266 | 153/116 | 7 | |
Data expressed by mean ± SD, median (IQR) or n/N. IQR = interquartile range. ALT: alanine aminotransferase (> 41 U/L). AST: aspartate aminotransferase (> 40 U/L). TBIL: total bilirubin (> 21 μmol/L). NAFLD: non-alcoholic fatty liver diseases. HBsAg: Hepatitis B virus surface antigen positivity
aPatients based on AST > 40U/L
bPatients based on ALT > 50U/L
cPatients based on TBIL > 17.1 μmol/L
dPatients based on abnormal liver test (Group A) and liver injury (Group B)
eComplication liver dysfunction included 44 non-severe and 62 severe patients